Compare Natera Inc. Common Stock (NTRA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Orion Office REIT Inc — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Orion Office REIT Inc trades at $2.11 (market cap $119.79M). The key difference: Natera Inc. Common Stock is far larger — about 476.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Orion Office REIT Inc for 34 Days on average.
| NTRA | ONL | |
|---|---|---|
Market Cap | $57.03B | $119.79M |
Volume | 1,131,157 | 347,277 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $3.00 |
52-Week Low | $179.42 | $1.93 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $56.18B | $536.73M |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ONL trades at $2.10, down 2.33% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported Q2 2026 EPS of $0.42, beating expectations, but maintains negative net income margins and declining revenue trends from $208M in 2022 to $148M in 2025. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook remains challenging with persistent net losses and high debt levels, though the deep discount to book value (P/B 0.19) offers potential upside if operational improvements materialize. Key risks include ongoing revenue contraction, negative profitability, and significant leverage exposure in the office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
